Study of Wilms Tumors Among Patients of Shefa Al-Orman Children Cancer Hospital
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Overall-survival (OS)
研究概览
简要总结
The goal of this cross sectional observational study is to determine the percentage of Wilms tumors among pediatric cancers at Shefa Al-Orman Children Cancer Hospital from june 2020 to june 2024,to study the outcome of patients with Wilms tumor treated according to SIOP Umbrella protocol during the study period and to study the treatment related complications during therapy according to common terminology criteria of adverse events version 5.0 (CTCAE Version 5.0).
详细描述
Research Design and Methods:
Study design: cross sectional study Study setting: Shefa Al-Orman Children Cancer hospital Study period: from June 2020 to June 2024
Study Objectives:
- To determine the percentage of Wilms tumors among pediatric cancers.
- To study the outcome of patients with Wilms tumor treated according to SIOP Umbrella protocol (1).
- To study the treatment related complications during therapy according to common terminology criteria of adverse events version 5.0 (CTCAE Version 5.0) (2).
Data collection: Each patient is subjected to all the following according to the centre policy:
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- — 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Children and young adolescene younger than 18 years of age admitted and treated at Shefa Al-orman Children Cancer Hospital during the study period
排除标准
- •Patients aged older than 18 years old, died early at presentation before starting chemotherapy, patients with non-Wilms renal tumors, relapsed renal tumors.
结局指标
主要结局
Overall-survival (OS)
时间窗: from date of diagnosis to last date of follow up or date of death for any cause
will be calculated from date of diagnosis to last date of follow up or date of death for any cause
次要结局
- Event-free survival (EFS)(the date of Wilms tumor diagnosis to the first treatment failure or date of last follow-up. Treatment failure included abandonment of treatment, death, and progressive or relapsed disease.)
研究者
Mahmoud Motaz Elzembely
Lecturer of Pediatric Hematology Oncology
South Egypt Cancer Institute